TNXP Tonix Pharmaceuticals
- 0.1811
- +0.0100+5.84%
Tonix Pharmaceuticals News
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase April 24, 2024 8:00am EDT Download as PDF CHATHAM, N.J., April 24, 2024 (GLOBE NEW
Tonix Pharmaceuticals Q4 EPS $(0.86) Beats $(1.55) Estimate, Sales $3.80M Miss $5.75M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(1.55) by 44.52 percent. This is a 75.43 percent increase over losses o
Press Release: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent operational highlights.
Tonix Pharmaceuticals Stock (TNXP) Hits A New All-Time Low: What's Going On?
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares traded lower by 7.2% to $0.17 Monday morning, hitting a new-all time low. The stock is trading lower on downward momentum after the company last
12 Health Care Stocks Moving In Friday's Intraday Session
GainersAvalo Therapeutics (NASDAQ:AVTX) shares increased by 364.8% to $22.08 during Friday's regular session. The market value of their outstanding shares is at $17.6 million. Nexalin Technology (NASD
Why Tonix Pharmaceuticals Stock (TNXP) Is Getting Obliterated
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares are trading lower by 33.9% to $0.22 Thursday afternoon after the company announced the pricing of a $4.4 million registered direct offering.Toni
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering March 28, 2024 9:32am EDT Download as PDF CHATHAM, N.J., March 28, 2024
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation From The FDA For TNX-2900 For The Treatment Of Prader-Willi Syndrome
TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery Of Novel Next-Generation Oxytocin Analogues At The American Chemistry Society Spring 2024 Meeting
Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health in autism and social anxiety disorderTNX
Tonix Picks CMOs for Potential Launch of Fibromyalgia Drug
Tonix Pharmaceuticals Announces Selection Of Two Contract Manufacturing Organizations For The Launch And Commercial Manufacture Of Tonmya For Management Of Fibromyalgia; NDA Submission Planned For 2H Of 2024
Tonix Pharmaceuticals Announces Selection Of Two Contract Manufacturing Organizations For The Launch And Commercial Manufacture Of Tonmya For Management Of Fibromyalgia; NDA Submission Planned For 2H
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for The...
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya for the Management of Fibromyalgia
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya for the Management of Fibromyalgia March 20,
Tonix Pharmaceuticals Announces Transition To Fully Integrated Biopharmaceutical Company Expected On April 1, 2024
Zembrace SymTouch and Tosymra will be marketed by Tonix Medicines, Tonix's wholly-owned commercial subsidiaryCommercial capabilities prepare Tonix for the potential launch in 2025 of Tonmya for the ma
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024 March 19, 2024 8:00am EDT Download as PDF
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the 2024 BIO-Europe Spring Convention being held March 18-20, 2024 in Barcelona, Spain.
Tonmya Shows Promise in Phase 3 Fibromyalgia Study
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a biopharmaceutical company, has reported positive results from its Phase 3 RESILIENT study of Tonmya, a treatment for fibromyalgia.
Tonix Pharmaceuticals Announces Phase 3 RESILIENT Study Of Tonmya Met Its Primary Endpoint Of Daily Pain Reduction And Achieved Statistically Significant Improvements On All Size Key Pre-Speceified Secondary Endpoints
Tonix Pharmaceuticals Announces Phase 3 RESILIENT Study Of Tonmya Met Its Primary Endpoint Of Daily Pain Reduction And Achieved Statistically Significant Improvements On All Size Key Pre-Speceified Se
Tonix Pharmaceuticals Reports Improvement in "Brain Fog," in Fibromyalgia Patients Treated With Tonmya in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia
Tonix Pharmaceuticals Reports Improvement in "Brain Fog," in Fibromyalgia Patients Treated with Tonmya in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Contro
Tonix's PTSD Treatment Shows Promise in Early Study
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a biopharmaceutical company, announced results from a study indicating that its drug TNX-102 SL demonstrated nominal improvement in the severity of PTSD symptoms and sleep quality within the first four weeks of treatment.
Analysis
Price Target
No Data
